ifulgent Investor Presentation November 7, 2022 Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Disclaimer 2 Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the "Company") about future events based on current views and assumptions. Examples of forward-looking statements made in this presentation include, among oth ...

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Paul Kim - CFO Brandon Perthuis - Chief Commercial Officer Dr. Ray Yin - President and Chief Scientific Officer, Fulgent Pharma Conference Call Participants Dan Leonard - Credit Suisse Operator Hello and welcome to the Fulgent Genetics Q3 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. (exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other juris ...

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2022 Results Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Nicole Borsje - Investor Relations, The Blueshirt Group Ming Hsieh - Chairman and Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Lawrence Weiss - Chief Medical Officer Paul Kim - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Operator Good day and welcome to the Q2 2022 Fulgent Genetics Earnings Conference Call. As reminder, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. (exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. (exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdict ...

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Nicole Borsje - IR Ming Hsieh - CEO Brandon Perthuis - Chief Commercial Officer Larry Weiss - Chief Medical Officer Paul Kim - CFO Conference Call Participants Kevin DeGeeter - Oppenheimer David Westenberg - Piper Sandler Operator Good day and welcome to the Q1 2022 Fulgent Genetics Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference ...

iuloent Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Disclaimer 2 Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the "Company") about future events based on current views and assumptions. Examples of forward-looking statements made in this presentation include, among others, those related its anticipated growt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 | --- | --- | --- | |-------------------------------------------|-------------------|------------------------------------------ ...

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2021 Earnings Conference Call February 23, 2022 4:30 PM ET Company Participants Nicole Borsje - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Larry Weiss - Chief Medical Officer Conference Call Participants Kevin DeGeeter - Oppenheimer. Sung Ji Nam - BTIG David Westenberg - Piper Sandler Operator Good day and welcome to the Fourth Quarter 2021 Fulgent Genetics Earnings Conference ...